Levetiracetam Injection
Product Images NDC 65145-173

This text provides important information about a medication called Levetiracetam in 0.75% Sodium Chloride Injection. The medication is intended for intravenous infusion only and contains 1000 mg of levetiracetam per 100 mL. It should be infused over a period of 15 minutes. The solution includes sodium chloride, glacial acetic acid, and sodium acetate trihydrate. It is stored at 20°C to 25°C and should not be further diluted before use. The medication is supplied in a single-dose dual port bag with an aluminum overwrap and the container closure is latex-free. Before use, the overwrap should be checked for any damage, and the solution must be discarded if leaks are found.*

This text provides detailed information about a medication called Levetiracetam in 0.75% Sodium Chloride Injection, with a concentration of 1000 mg/100 mL (10 mg/mL). The prescription mentions that it is for intravenous infusion only and should be infused over a period of 15 minutes. The text also specifies the composition of each 100 mL, storage recommendations, and cautions regarding the use of plastic containers. Additionally, it includes the batch coding area dimensions and the contact information of the distributor.*

This text provides information about a medication named Levetiracetam in 0.54% Sodium Chloride Injection, with a concentration of 1500 mg/100 mL. It should only be administered via intravenous infusion over a period of 15 minutes. The solution also contains sodium chloride, glacial acetic acid, and sodium acetate trihydrate. The usual dosage instructions are available in the package insert. It is important to check for leaks before use and store between 20° to 25°C (68° to 77°F). The medication comes in a single-dose dual port bag with aluminum overwrap, and the container closure does not contain natural rubber latex. The product is manufactured in India and distributed by Caplin Steriles USA Inc.*

This is a description of a medication package for Levetiracetam in 0.54% Sodium Chloride Injection. The package contains 100 mL of solution with a concentration of 1500 mg/100 mL (15 mg/mL). It is intended for Intravenous Infusion only over a period of 15 minutes. The product is manufactured in India and contains water for injection, sodium chloride, glacial acetic acid, and sodium acetate trihydrate. The usual dosage instructions are provided in the package insert. Storage recommendations include keeping it at 20° to 25°C in a controlled room. The package also includes a caution against using plastic containers in series connections.*

This text provides information about Levetiracetam in 0.82% Sodium Chloride Injection for intravenous infusion. It includes details on dosage, administration, composition, cautionary notes, storage recommendations, and manufacturing information. The medication comes in a single-dose dual port bag with an aluminum overwrap and should be used within the specified temperature range. The container closure does not contain natural rubber latex. It stresses the importance of checking for leaks before use and discarding if found. The product is distributed by Caplin Steriles USA Inc. and is made in India.*

This text contains information about a Batch Coding Area of 73 x 20 mm for Levetiracetam in 0.82% Sodium Chloride Injection, with a concentration of 500 mg/100 mL for Intravenous Infusion Only. It provides details on the composition of the injectable solution, including Levetiracetam amount, sodium chloride, acetic acid, and sodium acetate trihydrate. The text also mentions storage recommendations, dosage instructions, and caution about plastic containers. The product is made in India by CAPLIN STERILES.*

This text provides statistical data comparing the efficacy of Levetiracetam with a placebo. The results show a decrease of 37.1% in one group and an increase of 39.6% in another, emphasizing statistical significance. Additionally, there are percentages and numbers for different variations being evaluated.*

This information shows the percentage of patients in different groups receiving either placebo, Levetiracetam 1000 mg/day, or Levetiracetam 2000 mg/day. The data suggests that the efficacy of Levetiracetam at both doses is statistically significant compared to the placebo group.*

This text provides data on the percentage values of 14.4% and 39.4% along with information about a placebo group and a group taking Levetiracetam at a dosage of 3000 mg per day. The comparison indicates that the Levetiracetam group showed statistical significance versus the placebo group.*

This is a comparison chart showing the percentage of patients in different groups, placebo and Lovetiracetam, along with the number of patients in each group (N = 84 for placebo and N = 79 for Lovetiracetam). The data suggests that Lovetiracetam had a statistically significant effect compared to placebo.*